Matsuyama Naohiro, Kirikae Teruo, Kirikae Fumiko, Hashimoto Masahito, Amano Ken-Ichi, Hayashi Shunji, Hirai Yoshikazu, Kubota Tatsuya, Nakano Masayasu
Shiraoka Chuo Sogo Hospital, Shiraoka, Saitama 329-0217, *Department of Infectious Diseases and Tropical Medicine, Research Institute International Medical Center of Japan, Shinjuku, Tokyo 162-8655, †Central Research Laboratory, Akita University School of Medicine, Akita 010-8543, ‡Department of Microbiology and §Department of Intensive and Critical Care Medicine, Jichi Medical School, minamikawachi-machi, Tochigi 329-0498, Japan.
J Med Microbiol. 2001 Oct;50(10):865-869. doi: 10.1099/0022-1317-50-10-865.
As assessed by the lipopolysaccharide (LPS)-specific chromogenic Limulus amoebocyte lysate (LAL) assay, Helicobacter pylori LPS extracted by the phenol-water procedure showed full potency to coagulate LAL, as did LPS from Salmonella minnesota and Escherichia coli. However, pretreatment of H. pylori LPS with polymyxin B, which easily destroys the endotoxic activity of enterobacterial LPS/lipid A, had little effect on the LAL coagulation activity, although the same treatment of E. coli LPS markedly diminished its activity. The H. pylori LPS induced very weak production of nitric oxide (NO) or tumour necrosis factor (TNF) by murine macrophages and TNF by human peripheral whole blood in vitro in comparison with S. minnesota LPS. These findings indicate that H. pylori LPS has the unique endotoxic characteristic of retaining full LAL coagulation activity with polymyxin B resistance, despite losing its endotoxic potencies such as the ability to induce NO and TNF production.
通过脂多糖(LPS)特异性显色鲎试剂(LAL)测定法评估,采用酚水法提取的幽门螺杆菌LPS与来自明尼苏达沙门氏菌和大肠杆菌的LPS一样,具有使鲎试剂完全凝固的能力。然而,用多粘菌素B预处理幽门螺杆菌LPS(多粘菌素B很容易破坏肠道细菌LPS/脂质A的内毒素活性),对LAL凝固活性影响很小,而同样处理大肠杆菌LPS则会显著降低其活性。与明尼苏达沙门氏菌LPS相比,幽门螺杆菌LPS在体外诱导小鼠巨噬细胞产生一氧化氮(NO)或肿瘤坏死因子(TNF)以及诱导人外周全血产生TNF的能力非常弱。这些发现表明,幽门螺杆菌LPS具有独特的内毒素特性,尽管失去了诸如诱导NO和TNF产生的内毒素效力,但仍保留了对多粘菌素B耐药的完全LAL凝固活性。